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Identity 
Other names: MGC26306; X104; ZO2; ZO-2 
HGNC (Hugo): TJP2 
Location: 9q21.11 
Local order: Telomeric to FXN gene (9q21.11). 
DNA/RNA 
Description 
TJP2 gene exists as a single copy in the human 
genome; it contains 25 exons and is predicted to span 
over approximately more than 90 Kb of the genomic 
DNA. 
Transcription 
Five isoforms of TJP2 have been identified: 
The A1 isoform (CDS: 3570 nt); lacks exons C and B 
The A2 isoform (CDS: 3129 nt); lacks exons C, B, 20 
and 21. 
The A3 isoform (CDS: 2979 nt); lacks exons C, B, 20, 
21, 22 and 23 and exhibits a longer exon 19 (979 vs 
213 bp, with a stop codon at bp 313). 
The C1 isoform (CDS: 3501 nt); lacks exon A. 
The C2 isoform (CDS: 3057 nt); lacks exons A, 20 and
21. 
 
Schematic diagram of the TJP2 gene comprising 25 exons (in grey) and transcript variants. The sizes in base pairs of exons (above) and 
introns (below) are shown. *Indicates the position of the start codons. Exons C and B are expressed from promoter C. These exons are 
non-coding and translations starts from the ATG located in exon 2. Exon A is transcribed from promoter A. Isoforms C lack 23 
aminoacids at the amino terminus in comparison with isoforms A. Exons 20 and 21 are alternatively spliced. 
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Isoforms, structure and interactions of TJP2. a) Five isoforms to TJP2 have been reported. A and C isoforms are products of alternative 
promoter usage. A2 and C2 are consequence of alternative splicing of exons 20 and 21. Translation of A3 ends in exon 19. However in 
A3 exon 19 has 979 instead of 213 bp and exhibits a stop codon at bp 313. This situation makes isoforms A3 end with a sequence of 33 
amino acids that are not present in any of the other TJP2 isoforms. Numbers refer to amino acids. b) TJP2 is a MAGUK protein with three 
PDZ domains, an SH3 module and a GK domain. Between the first two PDZ domains, a region rich in basic amino acids is found. After 
the GK domain in C terminus direction, an acidic region and a proline rich domain is present. The last three amino acids at the carboxyl 
end constitute a PDZ binding motif and the first 23 amino acid residues at the N-terminus are absent in C isoforms. Numbers refer to 
amino acids. c) TJP2 is a scaffold molecule that interacts with proteins that participate in cell adhesion, signaling and gene transcription. 
The names of these proteins and their site of interaction in TJP2 are indicated. 
 
Northern blot analysis done with different probes for
exons A and C reveals two TJP2 transcripts of the same 
size, approximately 4.5 Kb, that respectively 





The full length TJP2 protein consists of 1190 amino 
acids corresponding to a theoretical molecular weight 
of 133.958 kDa. This size is 16% smaller than the 
apparent molecular mass of 160 kDa determined by 
SDS/PAGE. The high proline content (7.1%) may be 
responsible for this anomalous electrophoretic 
migration. The protein contains three PDZ, one SH3 
and one GuK domain at its NH2 dlg-like terminal 
region, followed by a short COOH terminal non dlg-
like region that contains an acidic and a proline rich 
domain. The protein belongs to the MAGUK protein 
family. At the carboxyl terminal end of TJP2 the type I 
PDZ binding motif TEL is found. TJP2 is predicted to 
contain 1 nuclear localization signal (NLS; 106-122 aa) 
and no exportation signals (NES) following the 
consensus L/M/IX1-4L/V/IX 2-3L/V/IX 1-2L/I. 
Two isoforms named A and C arise from the activation 
of different promoters. In the A form the initiation 
codon located within a unique 5' end 189 bp sequence 
gives rise to a distinctive 23 aa segment, whereas in the 
C form the 5' end exhibits a 377 bp sequence that is not 
translated. In isoforms C translation starts from a codon 
that corresponds to the second ATG in isoforms A. 
Isoform A2 is generated by alternative splicing of 
isoform A1. It lacks amino acids 961-1108. 
Isoform A3 is generated by alternative splicing of 
isoform A1. It lacks amino acids 994-1190 and the 
sequence from amino acids 961 to 993 differs from 
isoform A1. 
Isoform C2 is generated by alternative splicing of 
isoform C1. It lacks amino acids 961-1108. 
Expression 
Normal tissue: At the mRNA level the A isoforms are 
abundant in the heart and brain whereas the C isoforms 
are expressed at a high level in kidney, pancreas, heart 
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and placenta. In brain and skeletal muscle only the A 
isoform is detectable, but there is no tissue where 
TJP2C is solely present. TJP2 protein is strongly 
expressed in epithelial and endothelial cells. During 
mouse embryogenesis at the 16 cell stage, TJP2 
assembles at the apico-lateral contact site of 
blastomeres for the first time. The half-life of TJP2 
protein varies according to the degree of confluence of 
the culture, thus in canine kidney MDCK cells half 
lives correspond to 8.7 and 19.1 hrs in sparse and 
confluent cultures respectively. 
Localisation 
Present at the cytoplasmic side of tight junctions i  
epithelial and endothelial cells. In proliferating cultures 
and in cells under environmental stress TJP2 is also
present at the nucleus. TJP2 enters the nucleus at the 
late G1 phase of the cell cycle and departs during 
mitosis. At the nucleus TJP2 exhibits a speckled 
distribution and co-localizes with splicing factor SC-35 
and the nuclear ribonucleo-protein scaffold attachment 
factor SAF-B. In fibroblasts TJP2 gives a punctate 
pattern at the cell borders, and in cardiac muscle cells it 
is detected at the intercalated discs. 
Function 
TJP2 is crucial during development as silencing 
inhibits blastocele formation in mouse embryos and 
knock out mice die shortly after implantation due to an 
arrest in early gastrulation. 
TJP2 silencing with siRNA delays in epithelial 
monolayers the arrival of tight junction proteins to the 
cell membrane, triggers the novo formation of leaky 
tight junctions and alters cell polarity, thus suggesting 
that TJP2 is critical for the correct assembly and 
function of tight junctions. TJP2 and TJP1 are 
redundant in their role as promoters of claudins 
polymerization into tight junction strands. 
TJP2 inhibits transcription of human cyclin D1 (CD1) 
gene, decreases CD1 protein levels due to an increased 
degradation of the protein at the proteosome, blocks 
cell cycle progression from G1 phase to S and in 
consequence inhibits cell proliferation. These 
observations favor the image of TJP2 as a tumor 
suppressor protein. 
Besides the above mentioned, the nuclear function of 
TJP2 remains elusive. It localizes in speckles with SC-
35 and associates to lamin B1, to transcription factors 
Jun, Fos, C/EBP and Myc, to SAF-B, a chromatin 
component involved in the assembly of transcriptosome 
complexes, and enhances the nuclear localization of 
ARVCF, an Armadillo-repeat protein that associates 
with classical cadherins in adherens junctions. 
Homology 
TJP2 shares the following homology and identity (in 
parenthesis) with TJP1: 68% (54%); TJP3: 63% (45%); 
PSD-95: 40% (25%) and Dlg: 40% (23%). 
Mutations 
Germinal 
Mutation 143T-->C, predicted to cause a valine to 
alanine substitution (V48A) in TJP2 produces the loss 




Microarray analysis indicates that in 70% of primary 




In ductal pancreatic cancer cell lines BxPC3, Capan2, 
CFPAC1, Colo357, Hs766T, MiaPaCa-2, PL3, PL4, 
PL7, PL8, PL10, PL11 and PL11, TJP2 gene is 
methylated. Instead TJP2 gene is not methylated in 
ductal pancreatic cancer cell lines AsPC1, Capan1, 
Panc1, PL1, PL5, PL6, PL9, PL13 and PL14. 
Treatment with the demethylating agent 5-aza-2'-
deoxycytidine (5 Aza-dC) induces TJP2 expression in 
MiaPaCa (8.51 fold) and in Panc1 (1.41 fold) cells but
not in AsPC1 and Hs766T. 
Methylation analysis by digestion with restriction 
endonucleases reveals aberrant hypermethylation in PA 
promoter of isoform TJP2A from bases -383 to 87, 
which contains 62 CpG dinucleotides, in a variety of 
human primary pancreatic duct carcinomas and in the 
neoplastic human pancreatic duct cell lines BxPC-3, 
CFPAC-1, Hs700T, Hs766T, MiaPaCa-2, Su.86.86. 
However, demethy-lation of the PA does not recover 
normal level of TJP2A protein expression in the 
neoplastic cell lines except Su.86.86. 
Isoform TJP2A is specifically missing in pancreatic 
adenocarcinoma samples and in human pancreatic duct 
carcinoma cell lines with the exception of line PANC-
1. 
Disease 
Pancreatic adenocarcinoma is a disease in which 
malignant cells form in the regions of the pancreas th t 
have gland like properties. Although the pancreas h 
exocrine and endocrine cells, about 95% of pancreati  
cancers begin in exocrine cells and more than 90% of 
tumors of the pancreas are ductal adenocarcinomas 
derived from the exocrine pancreatic ducts. Depending 
on the extent of the cancer at the time of diagnosis, the 
prognosis is generally poor with less than 5% of thse 
diagnosed still alive five years after diagnosis.  
Typically pancreatic cancer first metastasizes to 
regional lymph nodes, then to the liver and less 
commonly to the lungs, although it can also directly 
invade surrounding visceral organs or metastasize to 
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In a prostate microarray assay the promoter sequence of 
TJP2 from cancerous cell lines PC3, PC3M, PC3M-
Pro4, PC3M-LN4 and LNCaP showed a significantly 
diminished hybridization in comparison to normal 
prostate cell lines RWPE-1, MLcsv40 and 267B1, 
which indicates a greater methylation of the TJP2 
promoter in prostate cancer. However in prostate 
adenocarcinoma cell lines loss of TJP2A protein is rare. 
Disease 
Prostate is a gland in the male reproductive system 
located below the bladder and in front of the rectum 
that produces seminal fluid that nourishes and 
transports sperm. Most cells in the prostate gland are of 
the glandular type; therefore the adenocarci-noma is the 
most common type of cancer to occur in the prostate. In 
the United States prostate cancer is the most common 
type of cancer in men, affecting about one in 8. It 
appears mainly in older men. 
Colon cancer 
Note 
In colon cancer loss of TJP2A protein is rare. 
Disease 
Also called colorectal cancer or large bowel cancer, 
includes cancerous growths in the colon, rectum and 
appendix. It is the third most common form of cancer 
and the second leading cause of cancer related death in 
the Western world. Colon cancer is thought to arise 
from adenomatous polyps in the colon. Colon 
adenocarcinoma accounts for 95% of cases of colon 
cancer. Colon cancer is the fourth most common cancer 
of males and females in the United States. 
Breast cancer 
Note 
In comparison to normal cells, TJP2 is found at a much 
lower protein level in malignant breast epithelia. In 
cancerous breast TJP2 immunostaining becomes more 
diffuse and decreases in intensity. By quantitative PCR 
the level of TJP2 mRNA is slightly elevated in the 
breast tumor tissues compared to the controls, however 
this result is not statistically significant. 
Disease 
Breast cancer is a disease in which malignant cells 
form in the tissues of the breast. Each breast has 15-20 
sections called lobes, which have smaller sections 
named lobules. Lobules end in dozens of tiny bulbs that 
can produce milk. The lobes, lobules and bulbs are 
linked by thin tubes called ducts. The most common 
type of breast cancer is ductal carcinoma that begins in 
the cells of the ducts. Cancer that begins in the lob s or 
lobules is called lobular carcinoma and is more often 
found in both breasts. Because the breast is a glandul r 
tissue nearly all breast cancers are called adenocarci-
nomas. Breast cancer is the most common type of 
cancer in women, affecting about 1 in 8 women. 
Testicular in situ carcinoma 
Note 
Loss of blood-testis barrier integrity and a decreased 
protein level expression of TJP2 is detected in testicular 
in situ carcinoma. In addition, ZO-2 immunoreactivity 
became weak and diffuse at the blood testis barrier 
region and spread to stain the entire lateral site of 
Sertoli cells as well as their cytoplasm, indicating 
altered localization. 
Disease 
Testicular cancer is a disease in which malignant cells 
form in the tissues of one or both testicles. The testicles 
are 2 egg-shaped glands located inside the scrotum that 
produce testosterone and sperm. Germ cells within the 
testicles produce immature sperm that mature as they 
travel through a network of tubules and tubes into the 
epididymis. Almost all testicular cancers start in the 
germ cells. The testicular in situ carcinoma also kn wn 
as stage 0, is a noninvasive precursor of testicular germ 
cell tumors, which are the most common type of cancer 
in young men. In testicular in situ carcinoma, abnormal 
cells are found in the tiny tubules where the sperm cells 
begin to develop, and all tumor marker levels are 
normal at this stage. 
Lung squamous carcinoma 
Note 
Squamous cell carcinomas show a 76% decrease in 
mRNA level for TJP2. 
Disease 
Lung cancer is a disease that forms in the tissues of the 
lung. In the United States it is the second most comm n 
malignancy after prostate cancer in men and breast 
cancer in women. The two main types of lung cancer 
are small cell lung cancers and non-small cell lung 
cancers, which are diagnosed based on how the cells 
look under the microscope. One type of non-small cell 
lung cancer is the squamous cell carcinoma. This 
cancer begins in squamous cells which are thin, flat 
cells that look like fish scales. It is also called 
epidermoid carcinoma. Squamous cell carcinoma is the 
second commonest type of lung cancer, accounting for 
28% of all cases of lung cancer. 
Lung adenocarcinoma 
Note 
Lung adenocarcinomas exhibit a 72% decrease in  
the mRNA level of TJP2. 
Disease 
Lung cancer is a disease that forms in the tissues of the 
lung. In the United States it is the second most comm n 
malignancy after prostate cancer in men and breast 
cancer in women. The two main types are small and  
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non-small cell lung cancers, which are diagnosed based 
on how the cells look under the microscope. One typ 
of non-small cell lung cancer is the adenocarcinoma in 
which the cancer begins in the cells that line the alv oli 
and make substances such as mucus. Lung 
adenocarcinoma is the most common kind of lung 
cancer in smokers and non-smokers and in people 
under age 45, accounting for about 40% of all lung 
cancers. 
Familial hypercholanemia (FHC) 
Note 
Mutation 143T-->C, predicted to cause a valine to 
alanine substitution (V48A) in TJP2 produces the loss 
of the alpha-helical structure of PDZ1 domain of TJP2. 
This mutation reduces PDZ1 domain stability and 
ligand binding in vitro. Thus binding of PDZ1 domain 
of TJP2 to peptides corresponding to the six C-terminal 
amino acids from claudin 1, claudin 2, claudin 3, 
claudin 5 and claudin 7 is significantly reduced when 
V48A mutation is present. This mutation is associated 
with Familial Hypercholanemia (FHC). 
Disease 
Mutation 143T-->C, causing a valine to alanine 
substitution (V48A) in TJP2 is associated to Familial 
hypercholanemia (FCH). 
Familial hypercholanemia is characterized by elevatd 
serum bile acid concentrations, itching and fat 
malabsorption. In TJP2143C/143C individuals 
inheritance is oligogenic, with mutations in bile acid 
coenzyme A amino acid N-acyltransferase (BAAT), 
required for clinical disease. 
To be noted 
Note 
TJP2 is proposed to be a tumor suppressor gene 
because: 1) TJP2 protein and/or mRNA expression is 
either lost or decreased in pancreatic, prostate, breast 
and lung adenocarcinomas, in testicular in situ 
carcinoma and in lung squamous carcinoma. 2) Has 
40% homology to the tumor suppressor gene Dlg. 3) 
TJP2 is target of the major oncogenic determinant E4-
ORF1 of human adenovirus type 9 (Ad9). E4-ORF1 
has a PDZ binding motif that sequesters TJP2 in the 
cytoplasm blocking its localization at the TJ. 
Additionally the over-expression of TJP2 suppresses 
transformation by Ad9 E4-ORF-1, activated Ras V12 
and the polyomavirus middle T protein. 4) TJP2 over-
expression lowers the level of cyclin D1, blocks cell 
cycle progression from G1 to S and inhibits cell 
proliferation. 
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